SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma reports 51.57% rise in Q4 consolidated net profit

15 May 2025 Evaluate

Piramal Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2025.

The company has reported marginal rise of 1.53% in its net profit at Rs 277.27 crore for the quarter under review as compared to Rs 273.08 crore for the same quarter in the previous year. The total income of the company increased by 9.55% at Rs 1,729.31 crore for Q4FY25 as compared to Rs 1,578.49 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 51.57% rise in its net profit at Rs 153.50 crore for fourth quarter ended March 31, 2025 as compared to Rs 101.27 crore for the same quarter in the previous year. The total income of the company increased by 8.43% at Rs 2,796.10 crore for Q4FY25 as compared to Rs 2,578.74 crore for the corresponding quarter previous year.

For the year ended March 31, 2025, the company has reported 76.73% rise in its net profit at Rs 691.40 crore as compared to Rs 391.22 crore for the previous year. The total income of the company increased by 19.62% at Rs 5,493.06 crore for year under review as compared to Rs 4,592.17 crore for year ended March 31, 2024.

For the year ended March 31, 2025, on the consolidated basis, the company has reported over five-fold jump in its net profit at Rs 91.13 crore as compared to Rs 17.82 crore for the previous year. The total income of the company increased by 11.26% at Rs 9,285.99 crore for year under review as compared to Rs 8,346.55 crore for year ended March 31, 2024.

Piramal Pharma Share Price

148.75 -0.15 (-0.10%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×